Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 925 INR 0.54%
Market Cap: 930.8B INR

Zydus Lifesciences Ltd
Long-Term Investments

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Zydus Lifesciences Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Long-Term Investments
₹16.4B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
48%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Long-Term Investments
₹10.8B
CAGR 3-Years
12%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Long-Term Investments
₹11.8B
CAGR 3-Years
25%
CAGR 5-Years
14%
CAGR 10-Years
16%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Long-Term Investments
₹40.4B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
22%
Lupin Ltd
NSE:LUPIN
Long-Term Investments
₹979m
CAGR 3-Years
-17%
CAGR 5-Years
-2%
CAGR 10-Years
33%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Long-Term Investments
₹710m
CAGR 3-Years
-5%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Zydus Lifesciences Ltd
Glance View

Zydus Lifesciences Ltd., a resilient player in India's pharmaceutical industry, traces its origins back to 1952, when it was founded in Ahmedabad. Over the decades, it has metamorphosed from a modest venture into a global healthcare presence, with a diverse repertoire that spans across pharmaceuticals, animal health, and consumer wellness products. The company's ethos is deeply embedded in innovation, steadfastly pursuing research and development to propel its pipeline of generics, novel therapeutics, and vaccines. With a robust manufacturing infrastructure spread across continents, Zydus ensures seamless distribution and availability of its products, thereby maintaining a key foothold in both established and emerging markets. The lifeblood of Zydus's profitability streams from its comprehensive product portfolio, catering to a myriad of therapeutic areas such as cardiology, gastroenterology, and women's health, among others. It generates revenue primarily through the sale of branded generics and active pharmaceutical ingredients (APIs). Strategic alliances and collaborations further bolster its growth trajectory, providing new avenues for market expansion and technological advancements. As the firm continues to navigate the complex landscape of global healthcare demands, it remains anchored to its core mission of delivering accessible and affordable healthcare solutions, ensuring that it not only sustains its economic pulse but also positively impacts countless lives worldwide.

ZYDUSLIFE Intrinsic Value
812.98 INR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Zydus Lifesciences Ltd's Long-Term Investments?
Long-Term Investments
16.4B INR

Based on the financial report for Sep 30, 2025, Zydus Lifesciences Ltd's Long-Term Investments amounts to 16.4B INR.

What is Zydus Lifesciences Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
48%

Over the last year, the Long-Term Investments growth was -7%. The average annual Long-Term Investments growth rates for Zydus Lifesciences Ltd have been 13% over the past three years , 13% over the past five years , and 48% over the past ten years .

Back to Top